Jeil Pharm - Asset Resilience Ratio
Jeil Pharm (002620) has an Asset Resilience Ratio of 2.93% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Jeil Pharm PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Jeil Pharm's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Jeil Pharm to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Jeil Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002620 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩25.77 Billion | 2.93% |
| Total Liquid Assets | ₩25.77 Billion | 2.93% |
Asset Resilience Insights
- Limited Liquidity: Jeil Pharm maintains only 2.93% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jeil Pharm Industry Peers by Asset Resilience Ratio
Compare Jeil Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Jeil Pharm (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Jeil Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.64% | ₩23.12 Billion ≈ $15.67 Million |
₩876.66 Billion ≈ $594.10 Million |
+0.83pp |
| 2024-12-31 | 1.80% | ₩16.06 Billion ≈ $10.89 Million |
₩890.43 Billion ≈ $603.43 Million |
-0.71pp |
| 2023-12-31 | 2.51% | ₩22.09 Billion ≈ $14.97 Million |
₩880.00 Billion ≈ $596.36 Million |
+0.36pp |
| 2022-12-31 | 2.15% | ₩18.64 Billion ≈ $12.63 Million |
₩865.68 Billion ≈ $586.66 Million |
+0.06pp |
| 2021-12-31 | 2.09% | ₩18.64 Billion ≈ $12.63 Million |
₩892.42 Billion ≈ $604.78 Million |
+0.99pp |
| 2020-12-31 | 1.10% | ₩9.78 Billion ≈ $6.63 Million |
₩887.40 Billion ≈ $601.37 Million |
+0.05pp |
| 2019-12-31 | 1.05% | ₩8.88 Billion ≈ $6.01 Million |
₩846.47 Billion ≈ $573.64 Million |
+0.65pp |
| 2018-12-31 | 0.40% | ₩3.69 Billion ≈ $2.50 Million |
₩920.09 Billion ≈ $623.53 Million |
-2.05pp |
| 2017-12-31 | 2.45% | ₩4.84 Billion ≈ $3.28 Million |
₩197.59 Billion ≈ $133.90 Million |
+1.81pp |
| 2016-12-31 | 0.64% | ₩3.15 Billion ≈ $2.14 Million |
₩491.98 Billion ≈ $333.41 Million |
-0.06pp |
| 2015-12-31 | 0.70% | ₩3.10 Billion ≈ $2.10 Million |
₩445.17 Billion ≈ $301.68 Million |
-1.86pp |
| 2012-12-31 | 2.56% | ₩9.99 Billion ≈ $6.77 Million |
₩390.77 Billion ≈ $264.82 Million |
-5.11pp |
| 2011-12-31 | 7.67% | ₩29.44 Billion ≈ $19.95 Million |
₩384.13 Billion ≈ $260.32 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more